TL;DR
Researchers have determined the high-resolution structures of amyloid-beta (Aβ42) filaments directly from human brains, revealing two distinct structural types (Type I and Type II) that are associated with different forms of Alzheimer's disease and other neurological conditions. This breakthrough provides crucial insights into the molecular basis of Aβ aggregation and opens new avenues for developing targeted therapies and diagnostic tools.
What Problem Does This Paper Address?
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-beta (Aβ) plaques in the brain. While it's known that Aβ42 peptides are a key component of these plaques and their assembly into filaments is central to AD pathogenesis, the precise three-dimensional structures of these filaments as they exist in the human brain have remained elusive. Previous structural studies often relied on in vitro assembled Aβ, which may not accurately reflect the in vivo structures. Understanding these native filament structures is critical for deciphering how they contribute to disease pathology and for developing effective interventions.
Methods
The primary technique employed in this study was cryo-electron microscopy (cryo-EM). This powerful method allows researchers to determine the atomic-level structure of biological molecules by imaging them at very low temperatures. Specifically, the authors extracted Aβ42 filaments from post-mortem human brain tissue and then used cryo-EM to capture high-resolution images. These images were processed using sophisticated computational methods, including helical reconstruction and Bayesian polishing, to generate 3D density maps of the filaments. Atomic models of the Aβ42 peptides within these filaments were then built and refined into these maps.
Other techniques used to complement the structural analysis included:
- Immunohistochemistry: To visualize the distribution of Aβ40 and Aβ42 in brain tissue.
- Immunoblotting and Mass Spectrometry (MALDI-TOF and LC-MS/MS): To confirm the composition of the extracted filaments (i.e., the ratio of Aβ42 to Aẞ40).
- Immunogold negative-stain electron microscopy: To further characterize the Aβ filaments.
Datasets
The study utilized brain tissue samples from ten individuals:
- Five individuals with Alzheimer's disease: three with sporadic AD and two with familial AD (carrying specific mutations in APP or PSEN1 genes).
- Five individuals with other neurological conditions: aging-related tau astrogliopathy (ARTAG), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and pathological aging (PA).
- Brains from homozygous App<sup>NL-F</sup> knock-in mice were also analyzed.
No new benchmark datasets were introduced; the study focused on analyzing native human brain samples.
Key Insights and Ideas
- Two distinct Aβ42 filament structures in human brain: The most significant finding is the identification of two structurally related but distinct types of Aβ42 filaments, termed Type I and Type II. This reveals a previously unrecognized level of structural heterogeneity in Aβ pathology.
- Differential association with disease types: Type I filaments were predominantly found in sporadic AD, while Type II filaments were more common in familial AD and other neurodegenerative conditions. This suggests that the specific structure of the Aβ filament might influence disease presentation or progression.
- In vivo structures differ from in vitro: The determined brain filament structures differ from those previously reported for in vitro assembled Aβ42. This highlights the importance of studying native samples to understand disease-relevant structures.
- Mouse model recapitulates human Type II: The App<sup>NL-F</sup> knock-in mouse model, which develops Aβ deposits, was found to have Type II filaments, suggesting its utility as a model for studying this specific fibril type.
- Potential for metal ion binding: The structures revealed densities consistent with bound metal ions, which may play a role in stabilizing the filament structure and potentially in aggregation.
Key Results
- Type I filaments: Characterized by an S-shaped protofilament fold, with the ordered core spanning residues G9-A42. These were found in the majority of filaments in sporadic AD cases.
- Type II filaments: Also feature an S-shaped protofilament fold, but with differences in the orientation of certain peptide groups and a slightly different core structure (V12-A42). These were prevalent in familial AD and other conditions.
- Protofilament packing: Type I protofilaments pack with pseudo-21 symmetry, while Type II protofilaments pack with C2 symmetry, stabilized by electrostatic interactions.
- Composition: Western blotting and mass spectrometry confirmed that the extracted filaments were predominantly composed of Aβ42, with variable amounts of Aẞ40.
- Resolution: The cryo-EM structures were determined at resolutions of 2.5 Å (Type I) and 2.8 Å (Type II), allowing for detailed atomic modeling.
Limitations and Future Work
- Limited sample size: While ten human cases were analyzed, the study acknowledges that a larger cohort would be beneficial for more robust statistical analysis and to capture the full spectrum of Aβ filament diversity.
- Presence of other Aβ species: The study did not find evidence for filaments composed predominantly of Aẞ40, but could not exclude their presence in low amounts or their extraction difficulties.
- Functional implications: While the structural differences are identified, the precise functional consequences of Type I versus Type II filaments on neuronal toxicity and disease mechanisms require further investigation.
The authors suggest that this knowledge will be instrumental in developing:
- Better in vitro and animal models: To more accurately mimic human disease pathology.
- Inhibitors of Aβ assembly: Targeting specific structural features of the filaments.
- Improved imaging agents: For more specific and sensitive detection of Aβ deposits in vivo.
Summary updated